Cullinan Therapeutics Clinical Trial Data
Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with refractory systemic lupus erythematosus (SLE). The data showed that 8 of 9 evaluable patients achieved clinically meaningful reductions in disease activity, with 4 of 7 patients with high baseline proteinuria achieving a complete renal response. The therapy demonstrated a favorable safety profile with no Grade 3 or higher cytokine release syndrome or neurotoxicity.
- Counterparty
- Chongqing Genrix Biopharmaceutical Co., Ltd.